Stent thrombosis (ST) is a major safety concern after
drug-eluting stent (DES) deployment, resulting in significant morbidity and mortality. The goal of this study was to examine the incidence, timing, clinical correlates, and outcomes after DES
thrombosis in a real-world population. A retrospective analysis of 8,402 patients who underwent
percutaneous coronary intervention and received a DES was performed. After DES implantation, 84 definite (DST) and 127 probable ST events occurred. The incidence of early DST was 0.8%, late DST was 0.4%, and very late DST was 0.4%. Multivariate analysis showed that a history of
diabetes mellitus,
myocardial infarction during admission, number of
stents, and DES placement in a restenotic lesion were independently associated with DST. The incidence of early definite or probable ST (
DPST) was 1.9%, late
DPST was 1.4%, and very late
DPST was 0.7%. Multivariate analysis showed that a history of diabetes,
myocardial infarction during admission,
cardiogenic shock, number of
stents, and DES use in a restenotic lesion were independently associated with
DPST. Both types of ST were associated with significantly higher rates of all-cause death, Q-wave
myocardial infarction, and revascularization up to 24 months after DES implantation. In conclusion, ST after DES implantation in contemporary practice continues to occur from 30 days to 2 years at a rate > or =0.36%/year and is associated with high rates of morbidity and mortality.
Diabetes mellitus,
myocardial infarction, and DES use in a restenotic lesion were strongly associated with DST; therefore, careful consideration should apply when deploying a DES in these populations.